UFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024. In the quarter to June 2026, revenue grew 15.1%, EPS grew 20.6%, free cash flow fell 35.8% and total debt fell 19.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow UFPT
UFP Technologies, Inc. (UFPT) EV/Sales
As of 16 October 2026, UFP Technologies, Inc. (UFPT) trades at a EV/Sales of 3.8×. Over the past ten years it has ranged from 0.8× (July 2015) to 6.7× (September 2024); the current reading is higher than 89% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | (25.38%) |
| FY2024 | 4.1× | 26.74% |
| FY2023 | 3.2× | 23.47% |
| FY2022 | 2.6× | (10.06%) |
| FY2021 | 2.9× | 60.02% |
| FY2020 | 1.8× | (2.00%) |
| FY2019 | 1.9× | 45.49% |
| FY2018 | 1.3× | 16.34% |
| FY2017 | 1.1× | 3.41% |
| FY2016 | 1.1× | 4.09% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.4× | 28.93% |
| Mar 2026 | 2.7× | (12.51%) |
| Dec 2025 | 3.1× | 8.53% |
| Sep 2025 | 2.8× | (18.50%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INSP Inspire Medical Systems, Inc. compare | 1.9× |
| NVCR NovoCure Limited compare | 2.0× |
| ATEC Alphatec Holdings, Inc. compare | 2.6× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| AXGN AxoGen, Inc. compare | 7.0× |
| ESTA Establishment Labs Holdings Inc. compare | 8.1× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)